Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

Albireo today announced that additional clinical data will be reported from a recent study assessing the safety, tolerability and efficacy of A3309 in patients with chronic constipation. A3309 is a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The results will be presented during the 2010 Digestive Disease Week (DDW) annual meeting being held in New Orleans, US.

The presentation was selected as a "poster of distinction", meaning that the poster was in the top 10% of all AGA Institute abstracts selected for poster presentation. In addition, a poster presenting the preclinical A3309 data has been accepted.

Details of the DDW session: Session Type: Poster Session Session Title: Constipation and IBS: Diagnosis and Treatment Session Date & Time: May 2, 2010 from 8:00 a.m. to 5:00 p.m. Title of the clinical abstract: The IBAT inhibitor A3309 - A Promising Treatment option for Patients with Chronic Idiopathic Constipation Title of the abstract describing preclinical findings: The IBAT inhibition by A3309 - A potential mechanism for the treatment of constipation

"The results show that A3309 was found to be safe and well tolerated and identified clear signs of improving colonic motility and bowel habits," said Magnus Simren, Principal Investigator (Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Sweden). "We are excited about the results of the trial, which confirms the potential that A3309 will benefit all those patients suffering from constipation and abdominal pain/discomfort who are refractory to OTC drugs," said Hans Graffner, Chief Medical Officer at Albireo. "The Albireo team looks forward to advancing the development of A3309, a first-in-class compound with a novel mode of action, and to create a new tool in the therapeutic armamentarium for these patients with limited treatment options."

A3309 is currently being evaluated in a large Phase IIb study in chronic constipation enrolling approximately 180 patients in the US and further investigation of A3309's enhancement of large bowel transit is being conducted at the Mayo Clinic. Also, given the mode of action, A3309 may be beneficial in patients with dyslipidemia and a study to evaluate A3309 in patients with high cholesterol levels is conducted in Sweden. Results of these clinical studies will be available late this year and plans are to move forward into Phase III in chronic constipation during 2011.

SOURCE Albireo AB